Contrasting Medicus Pharma (NASDAQ:MDCX) & Pluri (NASDAQ:PLUR)

Pluri (NASDAQ:PLUR) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Analyst Ratings

This is a summary of current ratings and price targets for Pluri and Medicus Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	0	0	1	0	3.00
Medicus Pharma	0	0	2	2	3.50

Pluri presently has a consensus target price of $12.00, suggesting a potential upside of 119.78%. Medicus Pharma has a consensus target price of $23.50, suggesting a potential upside of 982.95%. Given Medicus Pharma’s stronger consensus rating and higher possible upside, analysts clearly believe Medicus Pharma is more favorable than Pluri.

Profitability

This table compares Pluri and Medicus Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pluri	-2,563.29%	-4,191.91%	-85.40%
Medicus Pharma	N/A	-549.30%	-228.06%

Valuation and Earnings

This table compares Pluri and Medicus Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$330,000.00	130.21	-$20.89 million	($5.53)	-0.99
Medicus Pharma	N/A	N/A	-$11.16 million	($1.34)	-1.62

Medicus Pharma has lower revenue, but higher earnings than Pluri. Medicus Pharma is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

16.6% of Pluri shares are held by institutional investors. 25.9% of Pluri shares are held by company insiders. Comparatively, 11.2% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Medicus Pharma beats Pluri on 8 of the 13 factors compared between the two stocks.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.